In this report, EMEA Fibrinogen Concentrates Market will reach 217.15 Million USD by the end of 2022 with a CAGR of 8.76%
The EMEA Fibrinogen Concentrates market was valued at USD 142.72 million in 2017 and is expected to reach USD 217.15million by the end of 2022, growing at a CAGR of 8.76% between 2016 and 2022.
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s product are justly used in local region or countries.
Fibrinogen Concentrates can be divided into two categories—Animal Fibrinogen Concentrate type and Human Fibrinogen Concentrate type. Human Fibrinogen Concentrate type sales market share accounted for the higher proportion, with a figure of 99.05% in 2017, Animal Fibrinogen Concentrate type account for 0.95%.
By end user, the EMEA fibrinogen concentrate market is segmented into congenital fibrinogen deficiency and surgical procedures. In 2016, the Surgical Procedures application held the largest share in the EMEA market and accounted for a market share of 91.59%. The Surgical Procedures is major segmented into trauma patients, cardiovascular surgery patients, PPH patients, and plastic surgery patients.
XYZ research center data shows that Europe is the biggest contributor to the Fibrinogen Concentrates revenue market, accounted for 92.39% of the total EMEA market with a revenue of 131.85 million USD in 2017, followed by Middle East, 5.01% with a revenue of 7.15 million USD.
Allergan is the largest company in the EMEA Fibrinogen Concentrates market, accounted for 30.62% of the revenue market share in 2017, followed by Alcon (Novartis) and Abbott, accounted for 28.44% and 8.64% of the revenue market share in 2017.
The industry is high concentration and the key brands are mainly CSL Behring and LFB Group.
Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Fibrinogen Concentrates for these regions, from 2014 to 2026 (forecast), including
Germany
UK
France
Russia
Benelux
Italy
Spain
Europe Fibrinogen Concentrates market competition by top manufacturers/players, with Fibrinogen Concentrates sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
CSL Behring
LFB
...
On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
Animal Fibrinogen Concentrate
Human Fibrinogen Concentrate
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Fibrinogen Concentrates for each application, including
Congenital Fibrinogen Deficiency
Surgical Procedures
If you have any special requirements, please let us know and we will offer you the report as you want.
Summary:
Get latest Market Research Reports on Europe Fibrinogen Concentrates. Industry analysis & Market Report on Europe Fibrinogen Concentrates is a syndicated market report, published as Europe Fibrinogen Concentrates Market Report 2019. It is complete Research Study and Industry Analysis of Europe Fibrinogen Concentrates market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.